SERUM MYELOPEROXIDASE, MALONDIALDEHYDE, ALPHA-SYNUCLEIN LEVELS IN PATIENTS WITH EPILEPSY
Background: Processes such as neurodegeneration, hypoxia, blood brain barrier dysfunction and oxidative changes are effective for epileptogenesis.There is no non-invasive biomarker that can be used in the follow-up of patients with epilepsy, which is a neurodegenerative disease. Objective: In ou...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN ID |
| Publicado: |
University of Brawijaya
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b7263580af3a421b9d8d6206fc5601e8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Background: Processes such as neurodegeneration, hypoxia, blood brain barrier dysfunction and oxidative changes are effective for epileptogenesis.There is no non-invasive biomarker that can be used in the follow-up of patients with epilepsy, which is a neurodegenerative disease.
Objective: In our study, it was aimed to investigate the relationship between inflammatory, oxidative, neurodegenerative processes, and antiepileptic use in patients with epilepsy.
Methods: The groups were formed from the patients who were followed up in the epilepsy outpatient clinic between April 2019-June 2019, and the age-gender-matched control group.The study included 30 patients and 30 healthy volunteers. Venous serum samples were collected from groups to study myeloperoxidase, malondialdehyde and alpha-synuclein.
Results: The levels of myeloperoxidase and malondialdehyde were higher in the control group and this difference was statistically significant (p=0.003, p<0.001). The level of α-syn was higher in the epilepsy group and there was no statistically significant difference between the two groups (p=0.52). There was a positive correlation between the α-syn level and disease duration and as the disease duration increased, the level of α-syn increased (r=0.379, p=0.03).
Conclusion: Although the α-syn level increases with the duration of the disease in epilepsy patients, it is not a suitable parameter for use as a biomarker in the follow-up. |
|---|